Predictive value of bone scans in an adjuvant breast cancer program

Area of Science:

• Oncology
• Nuclear Medicine
• Radiology

Background:

• Accurate staging is crucial for determining adjuvant therapy in breast cancer patients post-mastectomy.
• Bone scans are utilized to detect metastatic disease, a key factor in treatment planning.

Purpose of the Study:

• To evaluate the utility of technetium 99m phosphate-complex bone scans for initial staging of breast cancer patients.
• To assess the predictive value of serial bone scan changes for early recurrence in patients receiving adjuvant therapy.

Main Methods:

• Technetium 99m phosphate-complex bone scans were performed on 43 women within two months of mastectomy for stages I-III breast cancer.
• Initial scans were analyzed for abnormalities, and eligible patients received adjuvant therapy.
• Serial bone scans were conducted at 6-month intervals for 36 patients, with clinical follow-up.

Main Results:

• Twelve percent of initial bone scans were abnormal or equivocal, leading to ineligibility for adjuvant therapy in 2 patients due to confirmed metastatic disease.
• Patients with unchanged serial bone scans showed no clinical recurrence (mean follow-up 20 months).
• Patients with changes in serial bone scans (new or disappearing lesions) had a significantly higher rate of clinical recurrence (p = 0.01, mean follow-up 43 months).

Conclusions:

• Technetium pyrophosphate bone scans are valuable for accurate initial staging in patients considered for adjuvant breast cancer treatment.
• Serial changes in bone scans effectively identify a high-risk group for early recurrence, informing clinical management.